(Q35700066)

9 August 2017

Assembly, structure, and antigenic properties of virus-like particles rich in HIV-1 envelope gp120. (English)

1 reference

9 August 2017

Ira Berkower

1

1 reference

9 August 2017

Megan Raymond

2

1 reference

9 August 2017

Jacqueline Muller

3

1 reference

9 August 2017

Angelo Spadaccini

4

1 reference

9 August 2017

Anne Aberdeen

5

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 March 2004

1 reference

9 August 2017

1 reference

9 August 2017

321

1 reference

9 August 2017

75-86

1 reference

9 August 2017

1

1 reference

Electron microscopic and solution X-ray scattering observations on the structure of hepatitis B surface antigen

9 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.017

Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.017

Neutralizing antiviral B cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.017

Human immunodeficiency virus 1. Predominance of a group-specific neutralizing epitope that persists despite genetic variation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.017

CD4-IgG binding threshold for inactivation of human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.017

Recombinant dengue virus type 2 envelope/hepatitis B surface antigen hybrid protein expressed in Pichia pastoris can function as a bivalent immunogen.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.017

A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.017

Cellular and Humoral Immunity in Guinea Pigs to Two Major Polypeptides Derived from Hepatitis B Surface Antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.017

Designing CD4 immunoadhesins for AIDS therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.017

Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), Is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.017

Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.017

A poliovirus neutralization epitope expressed on hybrid hepatitis B surface antigen particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.017

Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.017

Multiple topogenic sequences determine the transmembrane orientation of the hepatitis B surface antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.017

Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.017

Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.017

Relationship between antigenicity and immunogenicity of chimeric hepatitis B virus core particles carrying HIV type 1 epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.017

Codon usage limitation in the expression of HIV-1 envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.017

Novel anti-CD4 monoclonal antibodies separate human immunodeficiency virus infection and fusion of CD4+ cells from virus binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.017

Hepatitis B surface antigen assembles in a post-ER, pre-Golgi compartment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.017

Yeast retrotransposon particles as antigen delivery systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.017

Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.017

Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.017

Synergistic neutralization of a chimeric SIV/HIV type 1 virus with combinations of human anti-HIV type 1 envelope monoclonal antibodies or hyperimmune globulins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.017

Route of administration of chimeric BPV1 VLP determines the character of the induced immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.017

Use of DNAs expressing HIV-1 Env and noninfectious HIV-1 particles to raise antibody responses in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.017

Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Ev

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.017

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.017

Characterization of a Neutralizing Monoclonal Antibody to the External Glycoprotein of HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.017

Formation of HIV-1 envelope-hepatitis B core antigen hybrids with high affinity for CD4.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.017

Effect of the contents and form of rabies glycoprotein on the potency of rabies vaccination in cattle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.017

gp120: Biologic aspects of structural features

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.017

delta Agent: association of delta antigen with hepatitis B surface antigen and RNA in serum of delta-infected chimpanzees

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.017

An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.017

Neutralization of Divergent HIV-1 Isolates by Conformation-Dependent Human Antibodies to Gp120

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.017

Single-step assembly of a gene and entire plasmid from large numbers of oligodeoxyribonucleotides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.017

A topological model for hepatitis B surface antigen.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.017

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.017

Immunologic and Ultrastructural Characterization of HIV Pseudovirions Containing Gag and Env Precursor Proteins Engineered in Insect Cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.017

Cytotoxic T cells and neutralizing antibodies induced in rhesus monkeys by virus-like particle HIV vaccines in the absence of protection from SHIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.017

Skeptical scientists skewer VaxGen statistics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.017

Control of viremia and prevention of simian-human immunodeficiency virus-induced disease in rhesus macaques immunized with recombinant vaccinia viruses plus inactivated simian immunodeficiency virus and human immunodeficiency virus type 1 particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.017

The antigenic structure of the HIV gp120 envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.017

Mutational analysis of hepatitis B surface antigen particle assembly and secretion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.017

7 January 2021

Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.017

7 January 2021

Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.017

7 January 2021

Oligomeric organization of gp120 on infectious human immunodeficiency virus type 1 particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.017

7 January 2021

10.1016/J.VIROL.2003.12.017

Identifiers

DOI

1 reference

9 August 2017

1 reference